Everything below concerns DAC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The reliability of computer systems, that is the ratio of uptime to the sum of uptime and downtime. "Five nines" reliability in a continuously operated system means an average downtime of no more than approximately five minutes per year (there is no relationship between the number of nines and minutes per year, it is pure coincidence that "five nines" relates to five minutes per year.) (See high availability for a chart.) The purity of materials, such as gases and metals.
==== New Jersey ==== In 2007 the New Jersey Department of Environmental Protection (NJDEP) announced that it found PFOA at "elevated levels in the system's drinking water near DuPont's massive Chambers Works chemical plant". In 2018 the state published a drinking water standard for PFNA. Public water systems in New Jersey are required to meet a maximum contaminant level (MCL) standard of 13 ppt. In 2019 New Jersey filed lawsuits against the owners of two plants that had manufactured PFASs (the Chambers Works and the Parlin plant in Sayreville), and two plants that were cited for water pollution from other chemicals. The companies cited are DuPont, Chemours and 3M. In 2020 the NJDEP set a PFOA standard at 14 ppt and a PFOS standard at 13 ppt.
=== Minimum wage === During his 2022 gubernatorial campaign, Moore said that he would accelerate the state's incremental increase to a minimum wage of $15 an hour by 2023. He also supports indexing the state's minimum wage to inflation. At the beginning of the 2023 legislative session, Moore introduced the Fair Wage Act, a bill that would accelerate the state's minimum wage build-up to reach $15 an hour by October 2023 and index the minimum wage to the consumer price index starting in July 2025, with increases capped at five percent per year. The Senate Finance Committee amended the bill to remove provisions linking it to the consumer price index and delayed the wage increase until January 1, 2024. Moore signed the bill into law on April 11, 2023. He also allocated $218 million in his first budget to support state service providers in keeping up with the accelerated wage increase.
Dr. George D. Winter (1927–1981) was the British-born pioneer of moist wound healing. In 1962, while working at the Department of Biomechanics and Surgical Materials at the University of London, Winter published his landmark Nature paper Formation of the scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig (Nature 193:293 1962) where he demonstrated that, contrary to the conventional wisdom that wounds should be allowed to dry out and form scabs to promote healing, wounds instead healed faster if kept moist. Winter formed multiple partial thickness wounds on the backs of pigs, half left open to the air and half covered with a polymer film to keep them hydrated. The latter wounds healed faster, as measured by the migration of new epithelium on the wound bed. This work began the evolution of modern wound dressings that promote moist wound healing. George D. Winter was the first president of the European Society for Biomaterials and has an annual award named after him.
The hCG present in a woman's urine or blood is used to confirm pregnancy. Urine-based pregnancy tests detect hCG in the urine, while blood-based pregnancy tests measure the level of hCG in the blood. The presence of hCG in a woman's body indicates that a fertilized egg has implanted in the uterus and the placenta has started to form. 10 days after fertilization, significant hCG can be detected from woman's blood sample. The levels of hCG in the body increase rapidly in the first few weeks of pregnancy, doubling every 48–72 hours. The highest level of hCG is reached in week 10 or week 11, later the levels of hCG can be used to estimate the age of the fetus and monitor the progress of the pregnancy.
Sources: en.wikipedia.org
In 2015, about a million gunshot wounds occurred from interpersonal violence. Firearms, globally in 2016, resulted in 251,000 deaths up from 209,000 in 1990. Of these deaths 161,000 (64%) were the result of assault, 67,500 (27%) were the result of suicide, and 23,000 were accidents. Firearm related deaths are most common in males between the ages of 20 and 24 years. In 2016, the countries with the largest number of deaths from firearms are Brazil, United States, Mexico, Colombia, Venezuela, Guatemala, Bahamas and South Africa which make up just over half the total. In the United States in 2015, about half of the 44,000 people who died by suicide did so with a gun. As of 2016, the countries with the highest rates of gun violence per capita were El Salvador, Venezuela, and Guatemala with 40.3, 34.8, and 26.8 violent gun deaths per 100,000 people respectively. The countries with the lowest rates of were Singapore, Japan, and South Korea with 0.03, 0.04, and 0.05 violent gun deaths per 100,000 people respectively.
No animal species is known to be immune to the acute toxic effects of aflatoxins. Adult humans have a high tolerance for aflatoxin exposure and rarely succumb to acute aflatoxicosis, but children are particularly affected, and their exposure can lead to stunted growth and delayed development, in addition to all the symptoms mentioned below. High-level aflatoxin exposure produces an acute hepatic necrosis (acute aflatoxicosis), resulting later in cirrhosis or carcinoma of the liver. Acute liver failure is made manifest by bleeding, edema, alteration in digestion, changes to the absorption and/or metabolism of nutrients, and mental changes and/or coma. Chronic, subclinical exposure does not lead to symptoms as dramatic as acute aflatoxicosis. Chronic exposure increases the risk of developing liver and gallbladder cancer, as aflatoxin metabolites may intercalate into DNA and alkylate the bases through its epoxide moiety. This is thought to cause mutations in the p53 gene, an important gene in preventing cell cycle progression when there are DNA mutations, or signaling apoptosis (programmed cell death). These mutations seem to affect some base pair locations more than others; for example, the third base of codon 249 of the p53 gene appears to be more susceptible to aflatoxin-mediated mutations than nearby bases. As with other DNA-alkylating agents, Aflatoxin B1 can cause immune suppression, and exposure to it is associated with an increased viral load in HIV positive individuals.
=== Type 2 Diabetes === Failure in the regulation of glyceroneogenesis may lead to type 2 diabetes, a metabolic disorder that results in high levels of blood glucose and blood lipid. Type 2 diabetes, in addition to a decreased sensitivity to insulin, is associated with the overproduction of triglycerides in the liver, due to excessively active glyceroneogenesis and excess release of fatty acids from adipose tissues. Glyceroneogenesis can be regulated by controlling the gene expression of PEPC-K. Overexpressing PEPC-K in the liver will overproduce triglycerides and elevate the lipid level in the bloodstream, increasing the risk of fatty liver disease (hepatic steatosis). Conversely, in adipose tissue, down-regulated glyceroneogenesis may decrease de novo lipogenesis, increasing the export of free fatty acids to the bloodstream, leading to lipodystrophy. Both of these conditions are highly associated with type 2 diabetes.
In June 1950, American alarm over the Hukbalahap rebellion during the Cold War prompted President Harry Truman to approve special military assistance that included military advice, sale at cost of military equipment to the Philippines and financial aid under the Joint United States Military Advisory Group (JUSMAG). On August 26, 1950, in an "anniversary celebration" of the Cry of Pugad Lawin, the Huks temporarily seized Santa Cruz, Laguna, and Camp Makabulos, Tarlac, confiscating money, food, weapons, ammunition, clothing, medicine, and office supplies. In September 1950, former USAFFE guerrilla, Ramon Magsaysay was appointed as Minister of National Defense on American advice. With the Hukbalahap rebellion growing in strength and the security situation in the Philippines becoming seriously threatened, Magsaysay urged President Elpidio Quirino to suspend the writ of habeas corpus for the duration of the Huk campaign. On October 18, 1950, Magsaysay captured the Secretariat, including General Secretary José Lava, following the earlier capture of the Politburo in Manila. American assistance allowed Magsaysay to create more BCTs, bringing the total to twenty-six. By 1951, army strength had increased by 60 percent over the previous year with 1,047-man BCTs. Major military offensive campaigns against the Huks were carried out by the 7th, 16th, 17th, and 22nd BCTs.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.